BIOMAT Database Logo BIOMAT Database Logo

[Adriamycin in combination and in combined treatment modalities (author's transl)]. 1974

G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi

UI MeSH Term Description Entries
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma

Related Publications

G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].
September 1980, Klinische Wochenschrift,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Combined adriamycin and 5-fluorouracil therapy in the treatment of advanced cancer of the bladder (author's transl)].
January 1982, Medicina clinica,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Combined antidepressive treatment (author's transl)].
October 1981, Fortschritte der Neurologie-Psychiatrie,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Combination chemotherapy of anaplastic carcinoma with adriamycin, vincristine, methotrexate and cyclophosphamide (author's transl)].
January 1980, Bulletin du cancer,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Scheduled combination chemotherapy of adriamycin and BCNU to malignant brain tumors (author's transl)].
November 1976, Neurologia medico-chirurgica,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Combination chemotherapy in advanced malignant lymphoma with bleomycin, vincristine, adriamycin and prednisolone (author's transl)].
January 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[New cytostatics: bleomycin and adriamycin (author's transl)].
September 1973, Therapeutische Umschau. Revue therapeutique,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
January 1981, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Treatment modalities in sleep disorder--neurophysiological introduction and behavior modification (author's transl)].
January 1979, Wiener klinische Wochenschrift. Supplementum,
G Bonadonna, and G Beretta, and G Tancini, and M De Lena, and S Monfardini, and E Bajetta, and F Fossati Bellani, and C Brambilla, and U Veronesi
[Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)].
June 1978, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!